Beyond Patents: How to turn Intellectual Property into enterprise value in today's Biotech market

To celebrate London Life Science week, we are hosting, in collaboration with One Nucleus and 59 North, a breakfast networking event and panel discussion exploring how innovative biotech companies can transform intellectual property from a legal necessity into a strategic asset that drives valuation, investment and growth.

Tuesday 17 November | 8:30am - 10:30am
Marks & Clerk, Fetter Lane, London

In today's biotech market, breakthrough science alone is no longer enough. Investors, strategic partners and acquirers are placing greater emphasis on intellectual property as a key indicator of value, defensibility and long-term commercial potential.

Bringing together biotech founders, investors, pharmaceutical business development leaders and IP specialists, this discussion will examine how intellectual property influences fundraising outcomes, deal making and competitive positioning throughout a company's growth journey.

The panel will share practical insights into what investors and partners look for during diligence, how to build an IP strategy that supports enterprise value, and how emerging developments such as AI and changing global regulatory frameworks are reshaping innovation and ownership.

The session will conclude with an audience Q&A and networking.

Panel

• Confirmed: Mike Ward, Chair. Life Science Consultant
• Confirmed: Will Arends, Partner, Marks & Clerk
• Confirmed: Sten Sorensen, CEO, Cereno Scientific

Further panel members to be announced soon

Discussion Topics

The panel will explore:

• Why intellectual property has become a critical driver of biotech valuation.
• How investors assess the strength and commercial relevance of an IP portfolio.
• The role of IP strategy in successful Series A and later-stage fundraising.
• Common IP and diligence issues that can impact investment decisions.
• How biotech companies can create value beyond the next funding round.
• The implications of AI, evolving patent landscapes and global regulatory developments for life sciences innovation.
• What founders can do today to build a stronger, more investable business.

Key Takeaways

Attendees will gain:

• A deeper understanding of how intellectual property influences company valuation and investment decisions.
• Insight into current investor expectations in the biotech sector.
• Practical guidance on preparing for fundraising and due diligence.
• Perspectives from experienced founders, investors and IP specialists.
• Actionable strategies for building long-term enterprise value through innovation and IP.

Who Should Attend?

This event is designed for Biotech founders and leadership teams; Early-stage and growth-stage life sciences companies; Venture capital and investment professionals; R&D and innovation leaders.

Register Your Place

Places are limited and expected to fill quickly. Register now to apply for attendance. Once full we will add you to a wait list.

Register below.